Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
19 angezeigte Treffer · Seite 1, keine Gesamtzahl für „rucaparib“
Suchtreffer
Begriffe & Kennungen
Rubraca · 4.5 · 6 CYP3A substrates Rucaparib increased midazolam Cmax by 1.13 fold (90% CI: 0.95 to 1.36) and AUCinf by 1.38 f
Eintrag öffnenRubraca · 4.5 · BCRP substrates Rucaparib increased rosuvastatin Cmax by 1.29 fold (90% CI: 1.07 to 1.55) and AUCinf by 1.35 f
Eintrag öffnenRubraca · 4.5 · CYP1A2 substrates Rucaparib showed no effect on Cmax of caffeine while moderately increasing AUCinf of caffein
Eintrag öffnenRubraca · 4.5 · CYP2C19 substrates Rucaparib increased omeprazole Cmax by 1.09 fold (90% CI: 0.93 to 1.27) and AUCinf by 1.55
Eintrag öffnenRubraca · 4.5 · CYP2C9 substrates Rucaparib increased S-warfarin Cmax by 1.05 fold (90% CI: 0.99 to 1.12) and AUC0-96 h by 1.4
Eintrag öffnenRubraca · 4.5 · Effect of other medicinal products on rucaparib
Eintrag öffnenRubraca · 4.5 · Effects of rucaparib on other medicinal products
Eintrag öffnenRubraca · 4.5 · Enzymes responsible for rucaparib metabolism have not been identified. Based on in vitro data, CYP2D6, and to
Eintrag öffnenRubraca · 4.5 · In medicinal product interaction studies in cancer patients, the effects of steady-state rucaparib at 600 mg t
Eintrag öffnenRubraca · 4.5 · In vitro, rucaparib was shown to be a substrate of P-gp and BCRP. Effect of P-gp and BCRP inhibitors on rucapa
Eintrag öffnenRubraca · 4.5 · Interaction of rucaparib with other enzymes and transporter was evaluated in vitro. Rucaparib is a weak inhibi
Eintrag öffnenRubraca · 4.5 · Oral contraceptives Rucaparib increased ethinylestradiol Cmax by 1.09 fold (90% CI: 0.94 to 1.27) and AUClast
Eintrag öffnenRubraca · 4.5 · P-gp substrates Rucaparib showed no effect on Cmax of digoxin while marginally increasing AUC0-72 h by 1.20 fo
Eintrag öffnenRubraca · 4.8 · 9 to at least one dose of oral rucaparib in all clinical studies). In the placebo-controlled Phase 3 studies,
Eintrag öffnenRubraca · 4.8 · No studies have been conducted to investigate the pharmacokinetics of rucaparib in paediatric patients.
Eintrag öffnenRubraca · 4.8 · The overall safety profile of rucaparib is based on data from 1 594 patients in clinical trials in ovarian can
Eintrag öffnenrucaparib
Eintrag öffnenrucaparib camsylate
Eintrag öffnenrucaparib camsylate
Eintrag öffnen